Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution.
Saved in:
| Title: | Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution. |
|---|---|
| Authors: | Chay, W. Y.1,2 chay.wen.yee@singhealth.com.sg, Kumar, A.3, Hoskins, P. J.1, Tinker, A. V.1 |
| Source: | European Journal of Gynaecological Oncology. 2018, Vol. 39 Issue 6, p877-880. 4p. |
| Database: | Academic Search Ultimate |
| ISSN: | 03922936 |
|---|---|
| DOI: | 10.12892/ejgo4452.2018 |
